- Home
- NOTV vs CTSO Comparison
NOTV vs CTSO Comparison
Compare NOTV & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- CTSO
- Stock Information
- Founded
- NOTV 1974
- CTSO 1997
- Country
- NOTV United States
- CTSO United States
- Employees
- NOTV N/A
- CTSO N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- NOTV Health Care
- CTSO Health Care
- Exchange
- NOTV Nasdaq
- CTSO Nasdaq
- Market Cap
- NOTV 62.5M
- CTSO 57.6M
- IPO Year
- NOTV 1997
- CTSO N/A
- Fundamental
- Price
- NOTV $2.08
- CTSO $0.91
- Analyst Decision
- NOTV Strong Buy
- CTSO Buy
- Analyst Count
- NOTV 1
- CTSO 2
- Target Price
- NOTV $5.00
- CTSO $5.50
- AVG Volume (30 Days)
- NOTV 385.1K
- CTSO 301.1K
- Earning Date
- NOTV 08-06-2025
- CTSO 08-07-2025
- Dividend Yield
- NOTV N/A
- CTSO N/A
- EPS Growth
- NOTV N/A
- CTSO N/A
- EPS
- NOTV N/A
- CTSO N/A
- Revenue
- NOTV $480,402,000.00
- CTSO $35,332,238.00
- Revenue This Year
- NOTV $4.99
- CTSO $11.15
- Revenue Next Year
- NOTV $5.39
- CTSO $21.39
- P/E Ratio
- NOTV N/A
- CTSO N/A
- Revenue Growth
- NOTV N/A
- CTSO 15.37
- 52 Week Low
- NOTV $1.15
- CTSO $0.71
- 52 Week High
- NOTV $6.48
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- NOTV 50.54
- CTSO 41.67
- Support Level
- NOTV $1.86
- CTSO $0.77
- Resistance Level
- NOTV $2.15
- CTSO $1.06
- Average True Range (ATR)
- NOTV 0.20
- CTSO 0.08
- MACD
- NOTV 0.01
- CTSO -0.01
- Stochastic Oscillator
- NOTV 49.31
- CTSO 43.60
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.